Table 1 Non-Malignant Disorders Treated With Cord Blood

Hurler's syndrome

20

17 of the 20 children were alive a median of 905 days after transplantation, with complete donor chimerism and normal peripheral-blood alpha-L-iduronidase activity

Duchenne muscular dystrophy

1

On 42nd day, physical examination revealed obviously improvement in walking, turning the body over, and standing up

Malignant infantile osteopetrosis

1

Normalization of spine bone mineral density.

Rothmund-Thomson syndrome

1

Complete immune reconstitution

Buerger's disease

4

Ischemic rest pain suddenly disappeared. Digital capillaries were increased in number and size.

Spinal Cord Injury

1

Improved sensory perception and movement in the SPI patient's hips and thighs within 41 days of cell transplantation. Regeneration of the spinal cord at the injured site

Krabbe's disease

25

Progressive central myelination and continued gains in developmental skills, and most had age-appropriate cognitive function and receptive language skills in patient subset

Omenn syndrome

1

T cell reconstitution

Non-healing wounds

2

Accelerated healing

Refractory anemia

3

All patients are alive and free of disease at between 17 and 39 months after cord blood administration

Diamond-Blackfan anemia

1

Successful seroconversion to vaccines (diphtheria, pertussis, tetanus, rubella, measles, and BCG) administered 22–34 months post-transplant.

Severe chronic active Epstein-Barr virus

1

Complete remission without circulating EBV-DNA has continued for 15 months transplant.

Behcet's disease

1

Twenty-three months after CBT, the patient is doing well and has no signs or symptoms of Behcet's disease

Mucopolysaccharidosis type IIB (Hunter syndrome)

1

Two years after transplant approximately 55% normal plasma iduronate sulfatase. activity has been restored and abnormal urinary excretion of glycosaminoglycans has nearly completely resolved.